- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Amyloid light-chain (AL) amyloidosis
- Meeting Date: May 2022
- Public Summary Document (PSD) May 2022 PBAC Meeting - (PDF 1.7MB)
- Public Summary Document (PSD) May 2022 PBAC Meeting - (Word 823KB)
Daratumumab – May 2022
Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex SC® – May 2022
Last updated
26 August 2022